Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study123

https://doi.org/10.1093/ajcn/77.5.1318Get rights and content
Under an Elsevier user license
open archive

ABSTRACT

Background:

Elevated homocysteine concentrations, a likely risk factor for cardiovascular disease, can be lowered effectively with folic acid. The minimum dose of folic acid required for maximal reduction of homocysteine concentrations is not yet known reliably.

Objective:

We aimed to determine the lowest folic acid dose that decreases plasma homocysteine concentrations adequately in healthy older adults.

Design:

A dose-response trial with a randomized, double-blind, parallel-group, placebo-controlled design was carried out among 316 Dutch men and women aged 50–75 y. Subjects received daily for 12 wk either a placebo or 1 of the 6 following folic acid doses: 50, 100, 200, 400, 600, or 800 μg. The relative changes in plasma homocysteine concentration in response to increasing doses of folic acid were used to calculate the dose-response curve. An adequate dose of folic acid was defined as the dose that induced ≥ 90% of the maximal reduction in homocysteine concentration.

Results:

The relative decrease in plasma homocysteine concentration was associated exponentially with increasing doses of folic acid. From the dose-response curve, the adequate daily dose of folic acid was estimated to be 392 μg, which decreased plasma homocysteine concentrations 22%.

Conclusion:

In older adults, daily supplementation with folic acid effectively lowers plasma homocysteine concentrations, and a daily dose of ≈400 μg is the minimum dose required for adequate homocysteine reduction.

KEY WORDS

Folic acid
homocysteine
dose response
food fortification
dose-response curve
adult population

Cited by (0)

3

Address reprint requests to P Verhoef, Wageningen Centre for Food Sciences, c/o Division of Human Nutrition and Epidemiology, Wageningen University, Bomenweg 2, PO Box 8129, 6700 EV Wageningen, Netherlands. E-mail: [email protected].

1

From the Wageningen Centre for Food Sciences, Wageningen, Netherlands (FVAvO, AM-B, IAB, MBK, and PV); the Division of Human Nutrition and Epidemiology, Wageningen University, Wageningen, Netherlands (FVAvO, AM-B, IAB, CEW, MBK, and PV); the Department of Gastroenterology, University Medical Centre Nijmegen, Nijmegen, Netherlands (CEW); and the Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, United Kingdom (RC).

2

Supported by the Wageningen Centre for Food Sciences and the Dutch Organization for Scientific Research (MW 904-62-209).